Clinical Trials at the Summit

Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting held in Park City, Utah on June 8, 2024.

This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions.

To date, only the onset and enlargement of hyperTDs measured using en-face OCT imaging has been validated as a clinical trial endpoint.

Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Carl Danzig, MD, spoke with us about his presentation on the 24 week results of the PRISM trials for wet AMD. He gave this presentation at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Michael Singer, MD, spoke with Modern Retina about his presentation of first time data from the CALM Registry at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Eleonora Lad, MD, PhD, discusses the stages of dry AMD from early to intermediate to geographic atrophy, while also assessing which endpoints are most useful for these different stages.

Arshad M. Khanani, MD, MA, shares what attendees and the retina community can expect from the Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

The 12-month data demonstrated maintenance of controlled wet AMD subjects comparable to aflibercept injections every eight weeks with a single administration of OTX-TKI.

Senescent cells accumulate in areas of disease activity in DME and wet age-related macular degeneration and release mediators that drive the pathology. UBX1325 seems to prevent that disease activity.

Patients who are non-responders to anti-vascular endothelial growth factor (VEGF) therapy may benefit from intravitreal dexamethasone.

Ramin Tadayoni, MD, PhD, considers factors for choosing the right metrics and avoiding bias in clinical trials to prevent waste.

Arshad M. Khanani, MD, MA, MASRS, shares long-term data outcomes of patients treated with the port delivery system for neovascular AMD.

Tarek S. Hassan, MD, FASRS, provides an update on glycoimmunology as a next-generation treatment paradigm for geographic atrophy.

Caroline Baumal, MD shares an update on visual function data from DERBY and OAKS Studies based on her presentation at the 2023 Clinical Trials at the Summit annual meeting, held in Park City, Utah.

Margaret Chang, MD, MS, spoke with Modern Retina to give an update on avacincaptad pegol for geographic atrophy.

Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.